Home → Research News → Ask-the-Expert Conferences: Research News → June 2010: Updates from the 2010 ASCO Annual Meeting → News about PARP inhibitors for triple-negative cancers?

News about PARP inhibitors for triple-negative cancers?

Page last modified on: June 17, 2010

Question from MomOf4: Any new news this year about PARP inhibitors for triple-negative?: Answer —Andrew Seidman, M.D.: While we still await the data from a large randomized Phase III trial evaluating BSI-201, there were several smaller studies reported at this year's ASCO meeting. One study involved the oral PARP inhibitor olaparib, which was administered with weekly Taxol (chemical name: paclitaxel) chemotherapy for triple-negative metastatic breast cancer. (Abstract number 1018 at ASCO.) Another study examined yet another PARP inhibitor, veliparib, in combination with a chemotherapy agent called Temodar (chemical name: temozolomide). In this trial, significant responses were seen in patients with metastatic breast cancer who carried BRCA mutations. Still, to date there are no commercially available PARP inhibitors, and their ultimate role depends upon the awaited results of large randomized trials.

On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.

The materials presented in these conferences do not necessarily reflect the views of breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2008. All rights reserved.

Email Updates

Stay informed about current research, online events, and more.

Meet the Experts

Andrew D. Seidman, M.D. is an attending physician for the Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, and an associate professor of medicine at Joan and Sanford I. Weill Medical College of Cornell University.

Beth Baughman DuPree, M.D., F.A.C.S. the medical director of the Breast Health Program at Holy Redeemer Health System in Meadowbrook, PA.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

View Mobile Site